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The managment of metastatic neuroblastoma brings out ex-
tremes of view in paediatric oncologists. There is black pes-
simism from those who feel that little if any progress has
been made and question the value of more than gestural or
palliative treatment. This is in contrast to the excessive zeal
and optimism of others who enthusiastically publish
premature reports of 'advances' in survival. Screening infants
for urine catecholamine elevation may detect some early
stage patients (Draper, 1988) but whether it is a practical or
effective system to reduce the incidence of metastatic disease
remains to be proven. Until then chemotherapy remains the
most important component of management. But has any
progress been made in the past decade? Between 1970 and
1977, 61 patients with stage III (large unresectable primary)
or stage IV (metastatic disease) were treated at the Hospital
for Sick Children, Great Ormond Street, with the standard
VAC regimen. At 30 months after diagnosis, only 10% of
these patients were alive (Ninane et al., 1981). Following the
introduction of cisplatin, VM26 and consolidation with high
dose melphalan and autologous bone marrow rescue an
unselected cohort of simliar patients had a survival of 35%
at 30 months (Shafford et al., 1984). Eighteen per cent of
patients are alive in remission over 5 years later (Pritchard et
al., 1987). High dose melphalan with autologous bone mar-
row rescue was incorporated simultaneously with the OPEC
regimen (Shafford et al., 1984; McElwain et al., 1979; Hart-
mann et al., 1986) and it was unclear whether melphalan or
the introduction of cisplatin had improved outcome. To
clarify this, a prospective randomised study was designed by
the European Neuroblastoma Study Group (ENSG) and
remains one of the only randomised evaluations of
megatherapy. Patients who had achieved at least a partial
response with OPEC chemotherapy were randomised to
receive high dose melphalan as late consolidation or to have
no further chemotherapy. Local radiotherapy was not part of
the protocol. This study demonstrated significant prolonga-
tion of progression free survival in the patients receiving high
dose melphalan consolidation. Unfortunately, the curve has
subsequently turned out to be lozenge shaped although there
is still a small, but significant, survival advantage beyond 3
years. It should be emphasised, however, that the morbidity
of this procedure was low and the quality of life following
cessation of treatment was excellent. The median time to
relapse in the melphalan group was 2 years, compared with 6
months for the standard treatment arm (Pinkerton et al.,
1987).
Attempts to build on the base of high dose melphalan with
the addition of total body irradiation or other drugs at high
dose such as cisplatin, adriamycin, VP16, BCNU, pep-
tichimio have failed to have any dramatic impact (August et
al., 1984; Hartmann et al., 1987; Philip et al., 1987). Median
progression free survival, irrespective of high dose regimen, is
around 2 years.
The goal of many recent studies has been to improve the
initial response rate, attempting to increase CR rates above
the standard 40-50%. To this end, new agents such as
ifosfamide (de Kraker et al., 1987) and high dose cisplatin/
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VP16 (Philip et al., 1987) have been evaluated. A single agent
study with ifosfamide in relapsed patients showed minimal
activity but this was in heavily pre-treated patients who had
received high cumulative doses of cyclophosphamide and
many had relapsed following megatherapy. When introduced
as a single agent in previously untreated patients a response
rate of around 40% was reported (Kellie et al., 1988).
Whether this is superior to a comparable dose of cyclophos-
phamide cannot be concluded from historical data due to
differences in the stringency of restaging investigations. On
the assumption that ifosfamide permitted a higher dose of
alkylating agent be delivered at a lower cost in terms of
myelo suppression, this drug was introduced into a European
cooperative study (ENSG IIIC). High response rates in
relapsed patients had been reported several years ago, using
conventional dose cisplatinum in combination with VM26
(Hayes et al., 1981), and the demonstration in adults with
germ cell tumours that considerable dose escalation of cis-
platin was possible if the drug was given in divided doses
encouraged enthusiam about this approach in neuroblas-
toma. Fortunately, children are much less prone to the often
crippling peripheral neurotoxicity of high dose cisplatin seen
in adults and this regimen was well tolerated in phase III
studies (Hartmann et al., 1988). Ifosfamide/adriamycin and
high dose platinum/VP16 produces rapid clearing of meta-
static disease and, with surgery, produces CR rates around
60% (Pinkerton et al., 1990).
The dose of cyclophosphamide has also been escalated and
up to 4.8 g m-2 per course given. A clear dose effect is
apparent with a higher response rate using this schedule
compared to patients receiving half the dose (Kushner et al.,
1987).
Because of limited patient numbers, randomised studies,
even on a national basis, are difficult. Large randomised
American studies with minor variations in chemotherapy
have consistently failed to show significant differences. With
the more radical, high morbidity, regimens it is essential that
randomised comparisons are designed. Relying on historical
comparisons to support claims of improvements adds fuel to
the cynics' viewpoint.
Because of the lack of new active agents in this disease,
strategies have concentrated on different ways of using exis-
ting drugs. Recent interest has centered on high dose inten-
sity and rapid drug delivery protocols. The long term sur-
vival advantage for patients induced with high dose cisplatin/
VP 16 regimens is not yet clear but is probably going to turn
out to be marginal. This suggests that high dose intensity per
se has not had a major impact. The next step has been to
look at rapid dose delivery where the interval between
administration of active agents is reduced to a minimum.
This has been shown to be of value in germ cell tumours and
non Hodgkin's lymphoma. In a current UK pilot protocol
'NAPOLEON' (based on the Napoleonic 10 day calendar!)
high dose cisplatin is infused over 5 days with daily VP16
and this is followed, on day 10, by an infusion of standard
dose platinum and vincristine. On day 20 a cyclophos-
phamide based combination is given and chemotherapy is
repeated every 10 days for a total of 70 days, irrespective of
blood count. Encouraging initial response rates have been
reported but the study requires further follow-up (Pearson et
al., 1988).
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Currently, there is interest in the platinum analogue carbo-
plaiin which has been shown in a recent United Kingdom
Children's Cancer Study Group (UKCCSG) New Agent
Group study (NAG 1) to have some activity in cisplatin
resistant tumours (Pinkerton et al., 1989). Because of its
comparative lack of renal and oto-toxicity, considerable dose
escalation is possible (Gore et al., 1987; Pinkerton et al.,
1989). It remains to be demonstrated if in combination this
will add to melphalan alone. It is likely, however, that car-
boplatin will be introduced in many first line protocols but
with the proviso that greater myelosuppression may dose
limit combination chemotherapy.
Preliminary work indicates that P-glycoprotein overexpres-
sion may occur in refractory neuroblastomas (Hartmann et
al., 1989). Studies using calcium channel blockers are needed
to determine if this mechanism of chemotherapy resistance
can be overcome. Unfortunately, the MDR phenotype may
be a paraphenomenon associated with treatment induced
differentiation (Bates et al., 1989) and thus not of direct
relevance. There is, however, a suggestion that nifedipine
may enhance cisplatin sensitivity in neuroblastoma by a
mechanism not related to P-glycoprotein.
The specific uptake by monoiodobenzylguanidine (mIBG)
by adrenergic cells and therefore by many neuroblastoma
tumours has opened up the possibility of tumour directed
therapy. Such 'targeted' treatment has attracted wide pub-
licity and the idea of a 'magic bullet' has inevitable public
appeal. Although there is no debate about the value ofmIBG
imaging using either 1231 or 131I, the efficacy and value of
therapeutic mIBG remains to be clarified. Initial phase II
studies, predominantly from Dutch and German groups, pro-
duced encouraging response rates in refractory patients
(Treuner et al., 1987). These results were not, however, born
out by some other groups (Hartmann et al., 1987). The
UKCCSG has designed a study to evaluate the efficacy of 13'I
mIBG therapy for patients with unresectable residual
primary tumour after platinum based chemotherapy.
Although radiolabelled mIBG is designed as a tumour
specific therapy there is increasing concern about myelosup-
pression which occurs as the dose of "3'I is increased (Voute
et al., 1987). Prolonged thrombocytopenia may be seen, and
is not restricted to those with heavy marrow involvement at
the time of targeted therapy. This study is still under way but
to date there have been clear responses in this patient sub-
group. The future place of mIBG therapy may be as a final
consolidation with elective use of autologous bone marrow
rescue. Alternatively, earlier in the course of the disease using
lower and less myelosuppressive doses (Mastrangelo et al.,
1989). It remains to be demonstrated whether mIBG is an
effective modality for treating minimal residual bone marrow
disease or whether its usefulness is limited to residual
primary tumour or focal bony metastatic disease. This form
of therapy is expensive and requires, not only special shielded
isolation facilities, but also is labour intensive due to the
supervision required for the small children involved. For this
reason careful prospective studies such as that of the UKC-
CSG are essential.
The value of haemopoietic growth factors is yet to be
demonstrated in most paediatric treatment regimens but these
are likely to reduce treatment related neutropenia morbidity. It
is unlikely to improve efficacy as with the current high dose
intensity regimens myelosuppression is not the sole or even
major dose limited factor and, even with GCSF or GMCSF,
higher doses are unlikely to be able to be given. Moreover, the
absence of growth factors which significantly influence throm-
bocytopenia remains a major limitation although there is
optimism that IL3 (multi-CSF) may affect this.
Biological response modifiers may have a role, but studies
remain very preliminary. The American CCSG is currently
carrying out phase II studies with IL2 in relapsed tumours,
including neuroblastoma. Neuroblastoma cells do not express
HLA and might not, therefore, be expected to be susceptible
to IL2. Enhancing expression using interferon has been sug-
gested as a possible way of improving efficacy. The Lyon
group suggest that the appearance of 'LAK' like cells during
the early post auto-transplant period may facilitate IL2
activity in neuroblastoma (Favrot et al., 1989).
There has recently been a renewal of interest in
differentiating agents such as cis-retinoic acid (Hill, 1986). In
vitro studies with cell lines have demonstrated that the latter
will induce neurofibrillary differentiation in an
undifferentiated tumour (Thiele et al., 1985). Phase II studies
in relapsed patients with bulky disease are probably inappro-
priate for this treatment modality but there are anecdotal
reports of responses in patients with refractory marrow
involvement. The ENSG has chosen to evaluate cis-retinoic
acid in the setting of minimal residual disease and such
patients are randomised to daily cis-retinoic acid or placebo
for a 2-year trial period (ENSG IV study).
The appearance of new prognostic indicators such as
n-myc oncogene amplification, tumour-ploidy and chromo-
some 1 deletion and more sensitive ways of detecting meta-
static disease, such as mIBG scintigraphy (Moyes et al.,
1989) or magnetic resonance imaging (Couanet et al., 1988),
have thrown the classic staging systems for neuroblastoma
somewhat into disarray. The International Neuroblastoma
Staging System Working Party is currently engaged in keep-
ing up with these changes and has produced an interim
working system (Brodeur et al., 1988). This is, however,
already in need of updating. Without standardised staging
and response criteria comparison of results is difficult and in
a further 10 years time the cynics will remain cynics and the
zealots, zealots.
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